

PRODUCT
CANDIDATE

INDICATION

PRECLINICAL






PHASE I

PHASE II

PHASE III

EST 2018 GLOBAL
ADDRESSABLE
POPULATION






IMMUNOTHERAPY:

AG013	Oral Mucositis				850 K
AG020	Inflammatory Bowel Disease				> 4 M
AG018	Chronic Rhinosinusitis				12.3 M

DESENSITIZATION:

Research	Food, seasonal, perennial and venom allergy				
----------	---	---	--	--	--

TOLERANCE INDUCTION:

AG019	Type 1 Diabetes					> 70 K new cases per year
AG017	Celiac Disease					1.9 M

Phase Ib/IIa

ADDITIONAL PROGRAMS IN EARLY STAGE:

Research	Phenylketonuria					51 K
Research	Metabolic disease					
Research	Auto-immune Skin Disease					